Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole in PTSD
NCT04630444Phase 1Completed
- Sponsor
- McLean Hospital
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of riluzole in post-traumatic stress disorder (PTSD), sponsored by McLean Hospital. Primary endpoints: Clinical efficacy of riluzole in PTSD at 8 weeks and Effect on hippocampus biomarkers at 8 weeks. Started Mar 2017; status: completed.
02
Drugs
riluzole
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04630444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04630444.